Drugs / CMV-alphaDC1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05589844 | Mar 2023 → Nov 2024 | cytomegalovirus infection, hematopoietic and lymphoid system neoplasm | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV-alphaDC1 | “The CMV-alphaDC1 vaccine is made of white blood cells that have been exposed to molecules called cytokines, as well as CMV proteins.” NCT05589844 ↗ |
| Modality | Vaccine | “The CMV-alphaDC1 vaccine is made of white blood cells that have been exposed to molecules called cytokines, as well as CMV proteins.” NCT05589844 ↗ |
| Route | Other | “Given intradermally” NCT05589844 ↗ |